
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
| Company |
|---|
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
Orakl’s operational engine relies on a fast-growing platform that cultures, expands, freezes, and screens hundreds of patient-derived organoids (PDOs). As the Process Optimisation Intern, you will work with our laboratory, operations, and data teams to design and test new strategies that strengthen the robustness, efficiency, and scalability of this platform. Your role is to analyse our current workflows end-to-end and propose actionable improvements that enhance throughput, resource allocation, and cross-team coordination.
You will address practical and strategic questions essential to supporting Orakl’s rapid growth: how to streamline the duplication and expansion of PDOs; how to model the optimal number of lines that must be thawed or expanded at a given time; how to incorporate fresh samples into planning constraints; how to increase weekly screening capacity; and how to maintain high-quality traceability without burdening teams. You will work closely with wet-lab operators, the planning team, and data scientists to design prototypes, test ideas, and translate your findings into operational improvements.
Technical Interview (45 minutes call) – A deep dive into your technical skills and expertise relevant to the role.
Founder Interview: As final step of our recruitment process, you will meet the founders of Orakl Oncology in person at our office. This meeting is an opportunity for the founders to assess cultural fit and ensure alignment with our company values.